Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Oxymetazoline Cream in Rosacea
NCT02095158Phase 3Completed
- Sponsor
- Allergan
- Start
- Apr 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of AGN-199201 in rosacea, sponsored by Allergan. Primary endpoint: Percentage of Participants With Treatment-Related Adverse Events at 56 weeks. Started Apr 2014; status: completed.
02
Drugs
AGN-199201
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT02095158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095158.